Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc is positioned favorably due to its innovative approach in leveraging allogeneic gamma delta T cell therapies, particularly through its lead candidate, ADI-001, which shows significant efficacy in treating autoimmune diseases like lupus nephritis and systemic lupus erythematosus. The upcoming Phase 1 study of ADI-212 in metastatic castration-resistant prostate cancer, with initial data expected by the latter half of 2026, could serve as a critical value inflection point, highlighting the company's expanding oncology focus. Additionally, the decision to contract third-party manufacturers for commercial-scale production is anticipated to mitigate manufacturing risks, thereby supporting future growth and enhancing the overall investment outlook for Adicet Bio.

Bears say

Adicet Bio Inc is projecting a net loss of $1.13 per share for 2025, indicating ongoing financial challenges. The company faces significant risks, including potential negative clinical data, slower-than-expected development timelines, and a heightened regulatory risk due to the absence of FDA approvals for any Vδ1 gamma-delta T-cell therapies. Additionally, a lowered probability of success for ADI-001 in treating certain conditions, alongside competitive pressures that could dilute market share and revenue prospects, contribute to a negative outlook on the company's stock.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.